UroToday® launches an “Advanced Prostate Cancer Treatment Live” channel in the UrologyTUBE™

BERKELEY, CA USA (News Release) - January 14, 2015 - UroToday is expanding its video-on-demand content in the UrologyTUBE™ with a new video channel featuring multi-media lectures focusing on treatment of men with advanced prostate cancer. The new channel specifically focuses on androgen deprivation treatment (hormone treatment) as the backbone of advanced prostate cancer treatment. A number of well-known urologists and medical oncologists will be presenting video lectures with information about ADT, including clinical benefits, case presentations, and recent developments in our understanding of advanced prostate cancer. As the new channel launches, three video lectures are posted for the worldwide UroToday readership to access on UroToday.com. The first of the three video lectures features a presentation by Thomas Keane, MD, Chair of Urology at the Medical University of South Carolina (and Editor-in-Chief of UroToday), reviewing the rationale for ADT and evaluating the head to head trial of degarelix and leuprolide.

Prostate cancer treatment is a continuously evolving area in urology, and we remain committed to providing clinical evidence, by way of treatment-specific video content channels, as a means of keeping urologists and all health care providers up-to-date on cancer (mCRPC).

About UroToday

UroToday is an online urology reference that focuses on genitourinary malignancies, and all other urologic health conditions impacting men and women. Based in Berkeley, California, the website was founded in 2003 by Gina Carithers, CEO and publisher of its parent company, Digital Science Press, Inc. With more than 250 new content items posted every week, UroToday.com is the world’s largest and most comprehensive online urology resource and is accessible, at no charge, to all interested readers around the globe.